A large Germany‑based bioprocess company used our demand‑modeling intelligence to build a clear, volume‑based view of gene therapy APIs, enabling stronger capacity planning, lower investment risk and better alignment of technology platforms with high‑growth therapeutic indications.
Let's TalkWith gene therapy rapidly evolving into a high‑growth segment, the client sought to build a robust view of demand, translating clinical and commercial activity into projections that could confidently guide their long‑term investments in single‑use bioreactor platforms and process intensified manufacturing strategies
The fast-changing landscape of gene therapies hindered the client’s ability to estimate annual treatment volumes, quantify API requirements (in liters) and prioritize indications where demand justified capacity expansion on scalable single‑use production platforms
Uncertainty in API utilization from preclinical through commercial stages created ambiguities in scaling decisions, exposing the client to under‑ or over‑build single‑use and process intensified manufacturing capacity and reducing confidence in multi‑year facility and technology planning
